Comparing Biosig Technologies (NASDAQ:STEX) & Perspective Therapeutics (NASDAQ:CATX)

Perspective Therapeutics (NASDAQ:CATX) and Biosig Technologies (NASDAQ:STEX) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Risk and Volatility

Perspective Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Profitability

This table compares Perspective Therapeutics and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	N/A	N/A	N/A
Biosig Technologies	N/A	N/A	-64.96%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Perspective Therapeutics and Biosig Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	6	0	3.00
Biosig Technologies	1	0	0	0	1.00

Perspective Therapeutics currently has a consensus target price of $11.17, indicating a potential upside of 114.74%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Perspective Therapeutics is more favorable than Biosig Technologies.

Earnings & Valuation

This table compares Perspective Therapeutics and Biosig Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-5.78
Biosig Technologies	$40,000.00	13,246.80	-$10.33 million	($1.35)	-2.46

Perspective Therapeutics has higher earnings, but lower revenue than Biosig Technologies. Perspective Therapeutics is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by company insiders. Comparatively, 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Perspective Therapeutics beats Biosig Technologies on 6 of the 9 factors compared between the two stocks.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.